Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTR1E | P28566 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13124077 | 1.00 | SLC6A3 (0.58) | SLC6A3CHRNB4CHRNA3IDO1MEN1 | |
| SCHEMBL961019 | 0.98 | SLC6A3 (0.57) | SLC6A3CHRNB4CHRNA3IDO1MEN1 | |
| SCHEMBL961750 | 0.94 | SLC6A3 (0.53) | SLC6A3CHRNB4CHRNA3IDO1MEN1 | |
| SCHEMBL7355279 | 0.90 | CHRNB4 (0.53) | SLC6A3CHRNB4CHRNA3IDO1TRPA1 | |
| SCHEMBL17892330 | 0.87 | SLC6A3 (0.55) | SLC6A3CHRNB4CHRNA3IDO1MEN1 | |
| SCHEMBL7236223 | 0.81 | SLC6A3 (0.59) | SLC6A3CHRNB4CHRNA3MEN1KMT2A | |
| SCHEMBL8191324 | 0.81 | CHRNB4 (0.46) | SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL493477 | 0.81 | CHRNB4 (0.46) | SLC6A3CHRNB4CHRNA3IDO1MEN1 | |
| SCHEMBL3071813 | 0.81 | IDO1 (0.49) | SLC6A3IDO1MEN1KMT2APKM | |
| Hydrochloric Acid SCHEMBL2586181 | 0.80 | CHRNB4 (0.45) | SLC6A3CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | claimed |
| JP-4763788-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| US-20090062572-A1 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-05 | — | — | US | claimed |
| EP-1934167-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | Teva Pharmaceutical Industries Ltd. (IL) | 2008-06-25 | — | — | EP | claimed |
| WO-2008013993-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | WO | claimed |
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | claimed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | claimed |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| CN-109415306-A | The preparation method of 2- cyclohexylidene -2- phenylacetonitrile and its odorous analogue | 阿甘香气及精细化学有限公司 | 2019-03-01 | — | — | CN | disclosed |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0258617-B1 | 3,3-DISUBSTITUTED-PIPERIDINE-2,6-DIONE DERIVATIVES | MADAUS Aktiengesellschaft (DE) | 1992-03-18 | — | — | EP | disclosed |
| US-4839370-A | Novel derivatives of 3-aryl-3-cycloalkyl-piperidine-2,6-dione | ASTA-PHARMA AG (DE) | 1989-06-13 | — | — | US | disclosed |
| EP-0258617-A1 | 3,3-Disubstituted-piperidine-2,6-dione derivatives | MADAUS Aktiengesellschaft (DE) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | DNASE1L3, SERPINB1, BRDT | SLC6A3 4536/4885CHRNB4 4067/4885CHRNA3 3936/4885 |
| US-20090062572-A1 | Processes for the synthesis of O-desmethylvenlafaxine | CYP2D6, MAOB, CYP2C9 | SLC6A3 81/4885CHRNB4 531/4885CHRNA3 657/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | SLC6A3 4524/4885CHRNB4 1014/4885CHRNA3 1160/4885 |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | SLC6A3 4230/4885CHRNB4 4288/4885CHRNA3 4532/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | SLC6A3 4103/4885CHRNB4 4224/4885CHRNA3 4503/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | SLC6A3 4230/4885CHRNB4 4288/4885CHRNA3 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.